Epigenetic basis of cancer drug resistance.
作者信息
Aziz Moammir H, Ahmad Aamir
机构信息
James H. Quillen VA Medical Center, Johnson City, TN 37604, USA.
School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35205, USA.
出版信息
Cancer Drug Resist. 2020 Mar 19;3(1):113-116. doi: 10.20517/cdr.2020.06. eCollection 2020.
Abstract
摘要
相似文献
1
Epigenetic basis of cancer drug resistance.癌症耐药性的表观遗传基础。
Cancer Drug Resist. 2020 Mar 19;3(1):113-116. doi: 10.20517/cdr.2020.06. eCollection 2020.
2
Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells.逆转与多柔比星耐药性获得相关的表观遗传异常可恢复乳腺癌细胞对药物的敏感性。
Eur J Pharm Sci. 2018 Oct 15;123:56-69. doi: 10.1016/j.ejps.2018.07.028. Epub 2018 Jul 19.
3
Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.通过癌细胞重编程鉴定与化疗耐药相关的特定表观遗传改变。
Med Hypotheses. 2015 Dec;85(6):710-4. doi: 10.1016/j.mehy.2015.10.025. Epub 2015 Oct 27.
4
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.作为抗癌药物耐药性介质的表观遗传酶突变
Drug Resist Updat. 2022 Mar;61:100821. doi: 10.1016/j.drup.2022.100821. Epub 2022 Feb 18.
5
Drug resistance in colorectal cancer: An epigenetic overview.结直肠癌的耐药性：表观遗传学概述。
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188623. doi: 10.1016/j.bbcan.2021.188623. Epub 2021 Sep 1.
6
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.肿瘤发生中的表观遗传机制、肿瘤细胞异质性和耐药性。
Drug Resist Updat. 2012 Feb-Apr;15(1-2):21-38. doi: 10.1016/j.drup.2012.01.008. Epub 2012 Feb 20.
7
Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.纳米凝胶介导的联合组蛋白去乙酰化酶抑制剂和多柔比星的鸡尾酒药物递送克服了乳腺癌细胞的耐药性。
Drug Deliv Transl Res. 2018 Oct;8(5):1289-1299. doi: 10.1007/s13346-018-0556-y.
8
Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.表遗传学药物和抗癌药物序贯治疗通过激活 p21 基因表达而导致 G2/M 期阻滞，从而在克服乳腺癌细胞耐药性方面具有高度协同作用。
Mol Pharm. 2013 Jan 7;10(1):337-52. doi: 10.1021/mp3004622. Epub 2012 Dec 24.
9
Understanding the role of phenotypic switching in cancer drug resistance.理解表型转换在癌症药物耐药性中的作用。
J Theor Biol. 2020 Apr 7;490:110162. doi: 10.1016/j.jtbi.2020.110162. Epub 2020 Jan 14.
10
Epigenetic heterogeneity in cancer.癌症中的表观遗传异质性。
Biomark Res. 2019 Oct 31;7:23. doi: 10.1186/s40364-019-0174-y. eCollection 2019.
引用本文的文献
1
Understanding and overcoming multidrug resistance in cancer.了解并克服癌症中的多药耐药性。
Nat Rev Clin Oncol. 2025 Jul 29. doi: 10.1038/s41571-025-01059-1.
2
Epigenetic Drivers of Chemoresistance in Nucleobase and Nucleoside Analog Therapies.核碱基和核苷类似物疗法中化疗耐药性的表观遗传驱动因素
Biology (Basel). 2025 Jul 9;14(7):838. doi: 10.3390/biology14070838.
3
SETDB1: an emerging target for anticancer drug development.SETDB1：抗癌药物研发的新兴靶点。
Future Med Chem. 2025 Jan;17(2):153-155. doi: 10.1080/17568919.2024.2444869. Epub 2024 Dec 25.
4
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.从隐窝到癌症：结直肠癌发生和治疗策略的整体观点。
Int J Mol Sci. 2024 Aug 30;25(17):9463. doi: 10.3390/ijms25179463.
5
SETDB1 as a cancer target: challenges and perspectives in drug design.作为癌症靶点的SETDB1：药物设计中的挑战与前景
RSC Med Chem. 2024 Mar 19;15(5):1424-1451. doi: 10.1039/d3md00366c. eCollection 2024 May 22.
6
Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line.阿霉素与肼苯哒嗪及双硫仑对MCF - 7乳腺癌细胞系的协同联合作用
PLoS One. 2023 Sep 28;18(9):e0291981. doi: 10.1371/journal.pone.0291981. eCollection 2023.
7
Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects.基于肽的乳腺癌疫苗：最新进展与前景
Pharmaceuticals (Basel). 2023 Jun 25;16(7):923. doi: 10.3390/ph16070923.
8
Mass Spectrometry Contribution to Pediatric Cancers Research.质谱技术在儿科癌症研究中的应用
Medicina (Kaunas). 2023 Mar 20;59(3):612. doi: 10.3390/medicina59030612.
9
HER2/neu-Based Peptide Vaccination-Pulsed with B-Cell Epitope Induced Efficient Prophylactic and Therapeutic Antitumor Activities in TUBO Breast Cancer Mice Model.基于HER2/neu的肽疫苗接种——用B细胞表位脉冲处理——在TUBO乳腺癌小鼠模型中诱导了高效的预防性和治疗性抗肿瘤活性。
Cancers (Basel). 2021 Oct 1;13(19):4958. doi: 10.3390/cancers13194958.
10
Genomic and epigenomic evolution of acquired resistance to combination therapy in esophageal squamous cell carcinoma.食管鳞癌联合治疗获得性耐药的基因组和表观基因组进化。
JCI Insight. 2021 Sep 8;6(17):e150203. doi: 10.1172/jci.insight.150203.
本文引用的文献
1
The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.儿童急性淋巴细胞白血病中的表观基因组：耐药性与治疗机遇
Cancer Drug Resist. 2019 Jun 19;2(2):313-325. doi: 10.20517/cdr.2019.11. eCollection 2019.
2
Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.卵巢癌患者表观遗传变化引发的顺铂和卡铂耐药性。
Cancer Drug Resist. 2019 Jun 19;2(2):271-296. doi: 10.20517/cdr.2019.010. eCollection 2019.
3
Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation.柔红霉素可通过不依赖ICAD/CAD的DNA片段化作用消除诱导多能干细胞衍生的癌症干细胞。
Cancer Drug Resist. 2019 Jun 19;2(2):335-350. doi: 10.20517/cdr.2019.01. eCollection 2019.
4
Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer.细胞重编程和表观遗传失调在乳腺癌获得性化疗耐药中的作用
Cancer Drug Resist. 2019 Jun 19;2(2):297-312. doi: 10.20517/cdr.2018.11. eCollection 2019.
5
Overcome cancer drug resistance by targeting epigenetic modifications of centrosome.通过靶向中心体的表观遗传修饰克服癌症耐药性。
Cancer Drug Resist. 2019 Jun 19;2(2):210-224. doi: 10.20517/cdr.2018.010. eCollection 2019.
6
The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors.组蛋白赖氨酸去甲基化酶在癌细胞对酪氨酸激酶抑制剂耐药性中的作用。
Cancer Drug Resist. 2019 Jun 19;2(2):326-334. doi: 10.20517/cdr.2019.16. eCollection 2019.
7
Alkylating anticancer agents and their relations to microRNAs.烷化剂抗癌药物及其与微小RNA的关系。
Cancer Drug Resist. 2019 Mar 19;2(1):1-17. doi: 10.20517/cdr.2019.09. eCollection 2019.
8
Tumor Immunology and Tumor Evolution: Intertwined Histories.肿瘤免疫学和肿瘤进化：交织的历史。
Immunity. 2020 Jan 14;52(1):55-81. doi: 10.1016/j.immuni.2019.12.018.
9
Molecular profiling for precision cancer therapies.精准肿瘤治疗的分子谱分析。
Genome Med. 2020 Jan 14;12(1):8. doi: 10.1186/s13073-019-0703-1.
10
Towards personalized treatment for early stage HER2-positive breast cancer.针对早期 HER2 阳性乳腺癌的个体化治疗。
Nat Rev Clin Oncol. 2020 Apr;17(4):233-250. doi: 10.1038/s41571-019-0299-9. Epub 2019 Dec 13.
Zotero 插件